Ahmad Esmaillzadeh, Parvin Mirmiran, Masoud Mirhosseini, Fereidoun Azizi,
Volume 3, Issue 2 (16 2004)
Abstract
Background: Although dietary guidelines recommend increased intake of grain products to prevent chronic diseases, epidemiologic data regarding whole-grain intake associated with metabolic syndrome is sparse. This study was undertaken to evaluate the relationship between whole-grain intake, metabolic syndrome and metabolic risk factors in Tehran adults population.
Methods: In this cross-sectional study, 827 subjects aged 18-74 were randomly selected from participants of the Tehran Lipid and Glucose Study. Usual dietary intake was assessed using a semi-quantitative food frequency questionnaire and two 24-hour dietary recalls. BMI, FBS, blood pressure, hypertriglyceridemia, hypercholesterolemia, high LDL, low LDL, metabolic syndrome (according to ATP III guidelines) and hypertension (based on JNC VI) were assessed subjects were categorized on quartile cut-points of whole and refined grain intake.
Results: Mean (±SD) consumptions of whole- and refined grains were 93±29 and 201±57 g/d, respectively. Compared with subjects in the lower quartile category, those in the upper category of whole-grain intake had lower prevalence of metabolic risks. Conversely, those in the higher category of refined grain intake had higher prevalence of metabolic risk factors, except for diabetes. After controlling for confounders, a significant decreasing trend was observed for the risk of having hypertriglyceridemia [odds ratios among quartiles: 1.00,0.89, 0.74, 0.61, respectively], hypertension and metabolic syndrome. Higher consumption of refined grains were associated with higher risk of having hypercholestrolemia [1.00, 1.07, 1.19, 1.23), hypertriglyceridemia [1.00, 1.17, 1.49, 2.01), hypertension and metabolic syndrome.
Conclusion: Whole grain intake is inversely and refined grain intake is positively associated with the risk of developing metabolic syndrome. Recommendations to increase whole-grain intake may reduce the risk of developing metabolic syndrome.
Leila Zamanpour, Ebrahim Banitalebi, Seyed Ehsan Amirhosseini,
Volume 15, Issue 5 (7-2016)
Abstract
Background: The purpose of this study is to the comparison of the effect of 12 weeks of sprint training and concurrent aerobic and strength training on high sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α) and insulin resistance in women with diabetes mellitus (T2DM)
Methods: 52 overweight female type 2 diabetic patients (age; 45-60 years old and fasting blood glucose ≥ 126 mg/dl (7.0 mmol/l)) were assessed for eligibility. Participants were assigned to intense interval training group (N=17), concurrent resistance- endurance training group (N=17) and control group (N=18). The combined strength-endurance group did 12 weeks, three sessions per week endurance training with 60 % of maximal heart rate and two session resistance training with 70 % 1-RM. Intense interval training group did three session/week of 4-10 repetition of all out 30s Wingate on ergometer were included 10 weeks of concurrent resistance- endurance training and intense interval training.
Results: The results showed that following sprint training, there were significant changes in hs-CRP (p<0.001), but it wasn’t significant following concurrent training (p=0.062). According to results, TNF-α change were not significant in intense sprint (p=0.11) and concurrent training (p=0.23). Differences were not significant for the fasting blood glucose in the intense interval training groups (p=0.000). Serum insulin levels showed significant increases in the SIT (p<0.000) and concurrent training (p=0.000) significantly. The data showed significant differences in insulin resistance index (HOMA-IR) in intense interval training (p=0.000) and concurrent resistance- endurance training (p=0.008). ANCOVA test showed no significant difference in fasting blood glucose concentrations (P=0.171).
Conclusion: Intense sprint training compare to concurrent strength-endurance training can have better inflammatory status for patients with type 2diabete.